modafinil has been researched along with Psychoses in 15 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the efficacy and safety of modafinil on parkinsonism and excessive daytime sleepiness (EDS), as well as on negative symptoms and cognitive abilities in patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) in a randomized double-blind placebo-controlled 8-week study." | 9.17 | Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. ( Ancoli-Israel, S; Caligiuri, MP; Kash, TP; Liu, L; Lohr, JB; May, TA; Murphy, JD, 2013) |
| "The efficacy, safety and tolerability of adjunctive armodafinil for cognitive performance, and negative and affective symptoms, were examined in 60 patients with schizophrenia or schizoaffective disorder." | 9.15 | The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. ( Bobo, WV; Jayathilake, K; Meltzer, HY; Sim, MY; Woodward, ND, 2011) |
| "To evaluate the efficacy, tolerability, and safety of modafinil for negative symptoms, cognition, and wakefulness/fatigue in DSM-IV-diagnosed schizophrenia patients treated with clozapine." | 9.14 | Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. ( Cather, C; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Macklin, EA; Walsh, JP, 2009) |
| "Twenty subjects with DSM-IV schizophrenia or schizoaffective disorder were randomly assigned to double-blind treatment with modafinil or placebo for 8 weeks." | 9.12 | A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. ( Marder, SR; Peloian, JH; Pierre, JM; Wirshing, DA; Wirshing, WC, 2007) |
| "To assess the effects of modafinil on fatigue, symptoms, attention, working memory, and executive functioning in schizophrenia patients treated with psychotropic medications." | 9.11 | Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. ( Alvir, J; Gunduz-Bruce, H; Meyer, S; Rosenthal, MH; Schooler, NR; Sevy, S; Visweswaraiah, H, 2005) |
| "Schizophrenia is a severe mental disorder characterised by positive and negative symptoms." | 5.46 | Modafinil in schizophrenia: is the risk worth taking? ( Gago, J; Neto, D; Spínola, C, 2017) |
| "To examine the efficacy and safety of modafinil on parkinsonism and excessive daytime sleepiness (EDS), as well as on negative symptoms and cognitive abilities in patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) in a randomized double-blind placebo-controlled 8-week study." | 5.17 | Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. ( Ancoli-Israel, S; Caligiuri, MP; Kash, TP; Liu, L; Lohr, JB; May, TA; Murphy, JD, 2013) |
| "The efficacy, safety and tolerability of adjunctive armodafinil for cognitive performance, and negative and affective symptoms, were examined in 60 patients with schizophrenia or schizoaffective disorder." | 5.15 | The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. ( Bobo, WV; Jayathilake, K; Meltzer, HY; Sim, MY; Woodward, ND, 2011) |
| "To evaluate the efficacy, tolerability, and safety of modafinil for negative symptoms, cognition, and wakefulness/fatigue in DSM-IV-diagnosed schizophrenia patients treated with clozapine." | 5.14 | Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. ( Cather, C; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Macklin, EA; Walsh, JP, 2009) |
| "Twenty subjects with DSM-IV schizophrenia or schizoaffective disorder were randomly assigned to double-blind treatment with modafinil or placebo for 8 weeks." | 5.12 | A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. ( Marder, SR; Peloian, JH; Pierre, JM; Wirshing, DA; Wirshing, WC, 2007) |
| "To assess the effects of modafinil on fatigue, symptoms, attention, working memory, and executive functioning in schizophrenia patients treated with psychotropic medications." | 5.11 | Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. ( Alvir, J; Gunduz-Bruce, H; Meyer, S; Rosenthal, MH; Schooler, NR; Sevy, S; Visweswaraiah, H, 2005) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| "Psychotic disorders are considered chronic mental health issues." | 3.01 | [Use of psychoactive substances as a treatment for psychosis]. ( de Lucas-Moreno, MG; Serrano-Jiménez, E, 2023) |
| "Modafinil is a wake-promoting drug that has been shown to improve attention, memory and executive function in the healthy population and in patients with schizophrenia." | 2.77 | Effects of modafinil on cognitive functions in first episode psychosis. ( Barnett, JH; Jones, PB; Sahakian, BJ; Scoriels, L; Soma, PK, 2012) |
| "Modafinil is a wake-promoting drug that has been shown to improve emotion discrimination in healthy individuals and attention and executive function in schizophrenia." | 2.76 | Effects of modafinil on emotional processing in first episode psychosis. ( Barnett, JH; Cheng, F; Cherukuru, S; Fielding, M; Jones, PB; Lennox, BR; Murray, GK; Sahakian, BJ; Scoriels, L, 2011) |
| "Modafinil is a wakefulness-promoting agent that is known to be used off-label as a cognitive enhancer and for the treatment of attention deficit hyperactivity disorder (ADHD)." | 1.62 | Modafinil-induced psychosis in a patient with attention deficit hyperactivity disorder. ( Flavell, J, 2021) |
| "Schizophrenia is a severe mental disorder characterised by positive and negative symptoms." | 1.46 | Modafinil in schizophrenia: is the risk worth taking? ( Gago, J; Neto, D; Spínola, C, 2017) |
| "Narcolepsy is characterized by symptoms that include excessive sleepiness during the daytime, cataplexy, hypnagogic hallucinations and sleep paralysis." | 1.35 | Narcolepsy and psychotic states--a case report. ( Daliahu, Y; Melamed, Y; Paleacu, D, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Serrano-Jiménez, E | 1 |
| de Lucas-Moreno, MG | 1 |
| Flavell, J | 1 |
| Neto, D | 1 |
| Spínola, C | 1 |
| Gago, J | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| Lohr, JB | 1 |
| Liu, L | 1 |
| Caligiuri, MP | 1 |
| Kash, TP | 1 |
| May, TA | 1 |
| Murphy, JD | 1 |
| Ancoli-Israel, S | 1 |
| Lees, J | 1 |
| Applegate, E | 1 |
| Emsley, R | 1 |
| Lewis, S | 1 |
| Michalopoulou, P | 1 |
| Collier, T | 1 |
| Lopez-Lopez, C | 1 |
| Kapur, S | 1 |
| Pandina, GJ | 1 |
| Drake, RJ | 1 |
| Wu, P | 1 |
| Jones, S | 1 |
| Ryan, CJ | 1 |
| Michail, D | 1 |
| Robinson, TD | 1 |
| Freudenreich, O | 1 |
| Henderson, DC | 1 |
| Macklin, EA | 1 |
| Evins, AE | 1 |
| Fan, X | 1 |
| Cather, C | 1 |
| Walsh, JP | 1 |
| Goff, DC | 1 |
| Melamed, Y | 1 |
| Daliahu, Y | 1 |
| Paleacu, D | 1 |
| Scoriels, L | 2 |
| Barnett, JH | 2 |
| Murray, GK | 1 |
| Cherukuru, S | 1 |
| Fielding, M | 1 |
| Cheng, F | 1 |
| Lennox, BR | 1 |
| Sahakian, BJ | 2 |
| Jones, PB | 2 |
| Bobo, WV | 1 |
| Woodward, ND | 1 |
| Sim, MY | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 1 |
| Soma, PK | 1 |
| Sevy, S | 1 |
| Rosenthal, MH | 1 |
| Alvir, J | 1 |
| Meyer, S | 1 |
| Visweswaraiah, H | 1 |
| Gunduz-Bruce, H | 1 |
| Schooler, NR | 1 |
| Pierre, JM | 1 |
| Peloian, JH | 1 |
| Wirshing, DA | 1 |
| Wirshing, WC | 1 |
| Marder, SR | 1 |
| Teitelman, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia[NCT00573417] | Phase 4 | 40 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder[NCT00373672] | Phase 4 | 60 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for modafinil and Psychoses
| Article | Year |
|---|---|
[Use of psychoactive substances as a treatment for psychosis].
Topics: Antipsychotic Agents; Cannabidiol; Humans; Ketamine; Modafinil; Psychotic Disorders; Quality of Life | 2023 |
8 trials available for modafinil and Psychoses
| Article | Year |
|---|---|
Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzhydryl Compounds; Cognition Disorders; Disord | 2013 |
Calibration and cross-validation of MCCB and CogState in schizophrenia.
Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Attention; Benzhydryl Compounds; Calibration; Centra | 2015 |
Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Cl | 2009 |
Effects of modafinil on emotional processing in first episode psychosis.
Topics: Adolescent; Adult; Affect; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition; Cross | 2011 |
The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzhydryl Compounds; Cognition Disorders; Double-Blind Met | 2011 |
Effects of modafinil on cognitive functions in first episode psychosis.
Topics: Adult; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders; Doub | 2012 |
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.
Topics: Adult; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition; Cognition Diso | 2005 |
A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition; Double-Blind Method; Fema | 2007 |
6 other studies available for modafinil and Psychoses
| Article | Year |
|---|---|
Modafinil-induced psychosis in a patient with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2021 |
Modafinil in schizophrenia: is the risk worth taking?
Topics: Adult; Aged; Antipsychotic Agents; Benzhydryl Compounds; Cognition Disorders; Humans; Male; Middle A | 2017 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Modafinil-induced psychosis.
Topics: Adult; Benzhydryl Compounds; Humans; Male; Modafinil; Narcolepsy; Psychotic Disorders | 2008 |
Narcolepsy and psychotic states--a case report.
Topics: Antipsychotic Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Comorbidit | 2009 |
Off-label uses of modafinil.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzhydryl Compounds; Brain Injuries; Central Nervous | 2001 |